Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omega Marks The Alpha Of Perrigo’s OTC Brand Play

This article was originally published in The Tan Sheet

Executive Summary

The deal expands Perrigo’s distribution footprint from less than 10 to more than 40 countries, but also points toward marketing branded OTCs in some of Omega’s European markets. But another growth driver is in its generic OTC wheelhouse – retailers offering more store brand products, says Perrigo CEO Joseph Papa.

You may also be interested in...



Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth

Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.

Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth

Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.

Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier

Perrigo concealed problems related to its 2015 acquisition of Omega and over-inflated the firm’s resistance to generic drug pricing pressures in its defense against Mylan's tender, shareholder group Carmignac Gestion says in a lawsuit.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS107571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel